Arcus Biosciences Stock Quote RCUS - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

14.60

Bid

Ask

Volume

409,059

14.16 Day's Range 14.85

12.95 52 Week Range 25.47

Market Cap

1.328B

Previous Close

14.47

Open

14.37

Last Trade

83234

14.6

Last Trade Time

Financial Volume

$ 5,999,294

VWAP

14.6661

Average Volume (3m)

722,196

Shares Outstanding

90,953,011

Dividend Yield

PE Ratio

-4.33

Earnings Per Share (EPS)

-3.38

Revenue

117M

Net Profit

-307M

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule... Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.arcusbio.com

Headquarters

Camden, Delaware, USA

Founded

1970

Arcus Biosciences Inc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker RCUS. The last closing price for Arcus Biosciences was $14.47. Over the last year, Arcus Biosciences shares have traded in a share price range of $ 12.95 to $ 25.47.

Arcus Biosciences currently has 90,953,011 shares outstanding. The market capitalization of Arcus Biosciences is $1.32 billion. Arcus Biosciences has a price to earnings ratio (PE ratio) of -4.33.

Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers

Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population Arcus Biosciences...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.99	-6.35022450289	15.59	16.15	14.01	469721	15.02541994	CS
4	-1.72	-10.5392156863	16.32	16.42	13.57	637478	14.90704726	CS
12	-0.78	-5.07152145644	15.38	18.07	13.57	722196	15.84133377	CS
26	-0.81	-5.25632706035	15.41	20.31	13.57	766976	16.58164637	CS
52	-5.21	-26.2998485613	19.81	25.47	12.95	776922	17.26982836	CS
156	-18.43	-55.7977596125	33.03	49.1	12.95	852090	23.66330931	CS
260	6.14	72.5768321513	8.46	49.1	6.3	706743	24.02280914	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
DCAPUnity Wealth Partners Dynamic Capital Appreciation & Options ETF	20.10 (839.25%)	128.82k
RGCRegencell Bioscience Holdings Ltd	$ 15.15 (349.55%)	1.34M
ATPCAgape ATP Corporation	$ 0.2262 (58.18%)	107.32M
SLRXSalarius Pharmaceuticals Inc	$ 2.34 (51.95%)	60.04M
GSUNGolden Sun Health Technology Group Ltd	$ 7.46 (45.42%)	590.09k
FLYEFly E Group Inc	$ 1.1601 (-81.82%)	25.44M
RNAZTransCode Therapeutics Inc	$ 0.3035 (-61.70%)	9.78M
JAGXJaguar Health Inc	$ 1.755 (-58.90%)	15.47M
MIRAMIRA Pharmaceuticals Inc	$ 2.55 (-49.10%)	25.64M
IVPInspire Veterinary Partners Inc	$ 5.19 (-43.83%)	1.67M
SLNASelina Hospitality PLC	$ 0.026 (-29.73%)	220.33M
SPWRSunPower Corporation	$ 0.9514 (32.91%)	186.76M
NVDANVIDIA Corporation	$ 122.59 (-0.77%)	173.91M
ADILAdial Pharmaceuticals Inc	$ 1.3422 (26.62%)	160.04M
HOLOMicroCloud Hologram Inc	$ 0.588 (26.07%)	135.56M